Exercise and Escitalopram in the Treatment of Anxiety in Patients with Coronary Heart Disease: One Year Follow-Up of the UNWIND Randomized Clinical Trial

Figures

• 

  Figure 1. Comparison of scores on the HADS-A by treatment group at one year. Adjusted HADS-A anxiety scores at 1-year follow-up revealed that participants in the Escitalopram condition (ESC) had lower scores compared to Exercise (EX) (P = 0.006). Multiple regression analyses were used with 1-year HADS-A scores serving as the outcome variable controlling for the pre-treatment HADS-A score, age, sex, race, baseline diagnosis of anxiety disorder, history of myocardial infarction, and treatment group as the predictor of interest.

• 

  Figure 2. Comparison of scores on the HADS-D (left panel) and BDI-II (right panel) by treatment group at one year. Adjusted HADS-D and BDI-II Scores at 1-year follow-up revealed that participants in Escitalopram (ESC) had lower scores on the HADS-D (P = 0.004) and lower scores on the BDI-II (P = 0.004) compared to those participants randomized to Exercise (EX). It should be noted that depression scores were still lower for all groups compared to their pre-treatment levels for the BDI-II (baseline Exercise = 16.2; Escitalopram = 15.2; Placebo 17.7) and HAM-D (baseline Exercise = 6.4; Escitalopram 6.7; Placebo = 7.0). Multiple regression analyses were used with 1-year outcomes serving as the outcome variables for the HADS-D and BDI-II respectively, controlling for the pre-treatment level of the respective outcome, age, sex, race, baseline diagnosis of anxiety disorder, history of myocardial infarction, and treatment group as the predictor of interest.